Urgency to Expand SGLT2i Use in HF Heightened by More DELIVER Data
MedPage Today,
Meeting Coverage > HFSA Analyses continue to support wider adoption of dapagliflozin, researchers say by Nicole Lou, Senior…
Meeting Coverage > HFSA Analyses continue to support wider adoption of dapagliflozin, researchers say by Nicole Lou, Senior…
This transcript has been edited for clarity. Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE: Welcome and thank you for joining…
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a drug class beneficial for treating type 2 diabetes, kidney disease…
This transcript has been edited for clarity. Silvio Inzucchi, MD: Welcome to Medscape InDiscussion.
December 3, 2021 3.28pm GMT Authors Vassilios Vassiliou Professor of Cardiac Medicine, University of East Anglia Vasiliki…
– By Vassilios Vassiliou, Professor of Cardiac Medicine, University of East Anglia Half of people with heart failure have a…
Heart failure is one of the most common cardiac diseases, affecting more than 30 million people worldwide.
The ketogenic ("keto") diet, originally developed in the 1920s as an alternative treatment for pediatric epilepsy, remains a…
The ketogenic ("keto") diet, originally developed in the 1920s as an alternative treatment for pediatric epilepsy, remains a…